Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Assets: 2013-2025

Historic Assets for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $415.5 million.

  • Theravance Biopharma's Assets rose 16.67% to $415.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $415.5 million, marking a year-over-year increase of 16.67%. This contributed to the annual value of $354.2 million for FY2024, which is 7.29% down from last year.
  • Per Theravance Biopharma's latest filing, its Assets stood at $415.5 million for Q3 2025, which was down 2.48% from $426.0 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Assets ranged from a high of $763.5 million in Q3 2022 and a low of $343.6 million during Q1 2025.
  • For the 3-year period, Theravance Biopharma's Assets averaged around $400.9 million, with its median value being $382.0 million (2023).
  • Its Assets has fluctuated over the past 5 years, first surged by 89.40% in 2022, then slumped by 45.83% in 2023.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Assets stood at $374.8 million in 2021, then surged by 62.05% to $607.4 million in 2022, then crashed by 37.11% to $382.0 million in 2023, then fell by 7.29% to $354.2 million in 2024, then rose by 16.67% to $415.5 million in 2025.
  • Its last three reported values are $415.5 million in Q3 2025, $426.0 million for Q2 2025, and $343.6 million during Q1 2025.